We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Biocompatibles | LSE:BII | London | Ordinary Share | GB00B0L2JD04 | ORD 21 53/94P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 429.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMBII 25 January 2011 BIOCOMPATIBLES INTERNATIONAL PLC (the `Company' or `Biocompatibles') Exercise of options under the Biocompatibles International Group plc Executive Share Options Scheme 1995 and the Biocompatibles International Performance Share Plan Biocompatibles International plc announced on 24 January 2011 that at the first of the two court hearings required as part of the Scheme, the Court sanctioned the Scheme under Part 26 of the Companies Act 2006. As a result of the court sanction, all outstanding Options under the 1995 Executive Scheme became exercisable and the following Directors entered into transactions in the Company's Ordinary shares of 21 53/94 pence each ("shares") by exercising the following options under the scheme: Executive Director The Biocompatibles International Group plc Executive Share Options Scheme 1995 No of Exercise Date of Grant Approved/Unapproved options price Crispin Simon 31,250 GBP1.89 22.08.2001 Unapproved Crispin Simon 31,250 GBP1.89 22.08.2001 Unapproved Super Peter Stratford 30,000 GBP0.59 24.09.2001 Unapproved Additionally, as a result of the court sanction, all previously unvested awards under the Performance Share Plan have now vested in respect of all the Biocompatibles shares over which they subsist; and the following Directors entered into transactions in the Company's Ordinary shares of 21 53/94 pence each ("shares") by exercising the following awards under the Performance Share Plan: Executive Director The Biocompatibles International Performance Share Plan No of shares subject to the award Date of award Crispin Simon 130,000 20.09.2007 Crispin Simon 109,000 01.10.2008 Crispin Simon 85,000 11.09.2009 Ian Ardill 75,000 20.09.2007 Ian Ardill 63,000 01.10.2008 Ian Ardill 50,000 11.09.2009 Peter Stratford 75,000 20.09.2007 Peter Stratford 63,000 01.10.2008 Peter Stratford 50,000 11.09.2009 John Sylvester 75,000 20.09.2007 John Sylvester 63,000 01.10.2008 John Sylvester 50,000 11.09.2009 Crispin Simon As a result of these exercises, Mr Simon is deemed to be interested in 667,678 shares, representing 1.63% of the Company's issued share capital as of the date of this notification. Ian Ardill As a result of these exercises, Mr Ardill is deemed to be interested in 265,586 shares, representing 0.65% of the Company's issued share capital as of the date of this notification. Peter Stratford As a result of these exercises, Mr Stratford is deemed to be interested in 254,111 shares, representing 0.62% of the Company's issued share capital as of the date of this notification. John Sylvester As a result of these exercises, Mr Sylvester is deemed to be interested in 223,275 shares, representing 0.54% of the Company's issued share capital as of the date of this notification. The above notifications are made in accordance with DTR 3.1.4R(1). - ends - Contact: Biocompatibles Tel: +44 (0)1257 732645 Ian Ardill, Finance Director Lygia Jones, Assistant Company Secretary Dealing Disclosure Requirements Following the announcement made on Monday, 20 September 2010 that the Company is in an offer period for the purposes of the Takeover Code, the Company is required to restate the following: Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any paper offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any paper offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any paper offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a paper offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure. Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any paper offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any paper offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a paper offeror, they will be deemed to be a single person for the purpose of Rule 8.3. Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4). Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. If you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure, you should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129. END
1 Year Biocompatibles Chart |
1 Month Biocompatibles Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions